share_log

Maxim Group Initiates Coverage On Virpax Pharmaceuticals with Buy Rating, Announces Price Target of $4

Maxim Group Initiates Coverage On Virpax Pharmaceuticals with Buy Rating, Announces Price Target of $4

Maxim集团以买入评级启动对Virpax Pharmicals的报道,宣布目标股价为4美元
Benzinga Real-time News ·  2022/06/09 09:22

Maxim Group analyst Naz Rahman initiates coverage on Virpax Pharmaceuticals (NASDAQ:VRPX) with a Buy rating and announces Price Target of $4.

马克西姆集团分析师纳兹·拉赫曼以买入评级开始对Virpax Pharmicals(纳斯达克股票代码:VRPX)进行报道,并宣布目标股价为4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发